HENDERA
831152
Hengerda New Materials
300946
Fujian Nebula Electronics.,Ltd
300648
Cubic Digital Technology
300344
HNAC Technology
300490
CN Stock MarketDetailed Quotes
688212 Shanghai Aohua Photoelectricity Endoscope
- 42.35
- -1.67-3.79%
Market Closed Feb 18 15:00 CST
5.70BMarket Cap114.15P/E (TTM)
44.40High42.16Low12.02KlotVolume43.72Open44.02Pre Close51.68MTurnover0.89%Turnover Ratio98.49P/E (Static)134.59MShares66.2252wk High4.12P/B5.70BFloat Cap31.5152wk Low52.82Limit Up134.59MShs Float83.70Historical High35.22Limit Down5.09%Amplitude31.51Historical Low0.30Dividend TTM42.99Avg Price7.38KlotAsk0.71%Div YieldTTM100Lot Size4.08KlotBid
Shanghai Aohua Photoelectricity Endoscope News
Aohua Endoscopy (688212.SH): Received government subsidies of 8.1736 million yuan.
Gelonghui, February 14丨Auhua Endoscope (688212.SH) announced that the company recently received a VAT refund of 8.1736 million yuan for software products, which are all government subsidies related to revenue.
On February 10, A-shares investment warning rod | *Special Treat Da Pharmaceutical: Received a prior notice of proposed termination of the company's Stocks listing; Lianhua Holdings: The company does not directly or indirectly Hold equity in DeepSeek.
Shareholder Junyue Rixin No. 17 of Cangzhou Mingzhu plans to reduce its Shareholding by no more than 1%; Zhejiang JIULI Hi-tech Metals plans to reduce its Shareholding in Yongxing Special Materials Technology by no more than 3.00%; Shareholder Guojiao Beidou of Zhejiang Shengyang Science and Technology plans to collectively reduce its Shareholding by no more than 3%; Shareholders Junlian Xinkang and Gao Shen of Aohua Endoscope plan to collectively reduce their Shareholding in the company by no more than 3.00%; In 2024, the revenue from the computing business of New East New Materials will account for no more than 10% of the total revenue from its main business; Zhejiang Daily Digital Culture Group has no direct or indirect equity relationship with DeepSeek and has not engaged in any business cooperation; Lianhua Holdings does not directly or indirectly hold shares in DeepSeek; *ST Special Treat.
Auhua Endoscopy (688212.SH): Junlian Xinkang and Gao Shen plan to collectively reduce their shareholding by no more than 3.00% of the company's shares.
On February 7, 2023, Auhua Endoscopy (688212.SH) announced that Junlian Xinkang and Gao Sheng plan to reduce their shareholding in the company through centralized bidding and bulk Trade, with a total reduction of no more than 4,037,610 shares, accounting for no more than 3.00% of the company's total share capital. Among them, the shares reduced through centralized bidding will not exceed 1% of the total number of company shares and will be conducted within three months after three trading days from the date of this announcement; the shares reduced through bulk Trade will not exceed 2% of the total number of company shares and will also be conducted within three months after three trading days from the date of this announcement.
Auhua Endoscopy (688212.SH): The share buyback has not yet been implemented.
Gelonghui, February 6丨Aohua Endoscopy (688212.SH) announced that as of January 31, 2025, the company has not yet implemented this share repurchase.
Australian and Chinese Endoscopy: 2024 Annual Results Forecast
2024 Annual Results Forecast
Aohua Endoscopy (688212.SH): Net profit for 2024 is expected to decline by 59.59% to 72.81%.
Gelonghui, January 22nd丨Aohua Endoscopy (688212.SH) announced the performance forecast for the fiscal year 2024, expecting a net income attributable to the owners of the parent company to be between 15.73 million yuan and 23.38 million yuan. Compared to the same period last year, this represents a decrease of 34.4744 million yuan to 42.1244 million yuan, with a year-on-year decline of 59.59% to 72.81%. For this reporting period, it is expected that the net income attributable to the owners of the parent company, after deducting non-recurring gains and losses, will be between -12.74 million yuan and -5.09 million yuan. During the reporting period, the company continued to strengthen its marketing efforts.
Shanghai Aohua Photoelectricity Endoscope (SHSE:688212) Has A Pretty Healthy Balance Sheet
Aohua Endoscopy (688212.SH): Shareholder Appalachian has cumulatively reduced its shareholding by 1.42%.
On November 14, Gelonghui reported that Auhua Endoscope (688212.SH) announced that the company received a notice from its shareholder Appalachian on November 13, 2024. As of the date of this announcement, Appalachian has reduced its shareholding by a total of 1,914,722 shares through centralized bidding and block trading, accounting for 1.42% of the company's total share capital. This shareholding reduction plan has been completed.
Australia China Endoscopy (688212.SH) 41.8228 million shares of restricted shares will be listed for trading starting November 15th.
Aohua Endoscopy (688212.SH) announced that the restricted shares to be listed for the first time are part of the company's initial public offering...
Shanghai Aohua Photoelectricity Endoscope Co., Ltd.'s (SHSE:688212) Latest 6.0% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Olympus Endoscopy (688212.SH): Currently, overseas is still in the early stage.
Gelonghui on October 28th | Aohua Endoscopy (688212.SH) investor relations activity records show that due to its relatively small scale, the overseas market is still in the early stages. Since the beginning of this year, a series of products including the AQ-300 have been approved in multiple countries or regions, further developing access to overseas markets. The international marketing team is actively participating in various industry conferences and engaging in industry exchanges. Currently, the company's overseas markets are mainly located in Europe and other cost-effective markets. Both markets have increasing demand for soft lenses, so the company will continue to promote the development of overseas markets.
Third Quarter Report 2024
The reversal of previously recognized share-based payment expenses and significant increase in government subsidies led to a more than threefold increase in net income for Aohua Endoscopy in Q3.
Due to the third quarter reversal of previously recognized share-based payment expenses, coupled with large government subsidies, Aohua Endoscopy achieved a third-quarter net income attributable to the parent company of 31.6414 million yuan, a year-on-year increase of 345.17%. In the field of soft endoscopes where foreign manufacturers have a market monopoly, Aohua Endoscopy not only holds a place, but its products have also entered the markets of Germany, the united kingdom, south korea, and other countries.
Olympus Endoscopy (688212.SH): The net income for the first three quarters was 37.303 million yuan, a decrease of 17.45% year-on-year.
GeLongHui on October 24th announced the 2024 third quarter report, with the company's revenue in the first three quarters of 0.501 billion yuan, a year-on-year increase of 16.79%; net income attributable to shareholders of listed companies was 37.303 million yuan, a year-on-year decrease of 17.45%; basic earnings per share was 0.28 yuan.
Does This Valuation Of Shanghai Aohua Photoelectricity Endoscope Co., Ltd. (SHSE:688212) Imply Investors Are Overpaying?
Aohua Endoscopy (688212.SH): received government subsidy of 14.15 million yuan
On October 8, GeLongHui reported that Aohua Endoscopy (688212.SH) announced that on September 30, 2024, the company received a total of RMB 14.15 million in government subsidy funds, all of which are government grants related to income.
Aohua Endoscopy (688212.SH): Some senior executives plan to increase their shareholding in the company by no more than 6.2 million yuan.
On September 22nd, Gelonhui announced that the company recently received letters from the Vice General Manager and Secretary of the Board of Directors, Shi Xiaojiang, Vice General Manager Chen Peng, Vice General Manager Bao Hanjing, and Vice General Manager Wang Xiguang. Based on their confidence in the company's future stable development and recognition of the long-term investment value of the company's stocks, they plan to increase their shareholding in the company through the methods allowed by the Shanghai Stock Exchange system (including but not limited to centralized bidding, block trades, etc.) within 6 months starting from September 23, 2024. The total amount of the shareholding increase shall not be less than 3.7 million yuan (inclusive) and shall not exceed 6.2 million yuan.
Shanghai Aohua Photoelectricity Endoscope (SHSE:688212) Might Be Having Difficulty Using Its Capital Effectively
Aohua Endoscopy (688212.SH): Appalachian plans to reduce its shareholding in the company by no more than 1.42%.
Australia Hua Endoscope (688212.SH) announced that Appalachian plans to use centralized bidding and bulk...
